Skip to main content
IBEX $35.53 -0.84%
IBEX logo

IBEX · IBEX Ltd

Track IBEX — free
$35.53 -0.30 (-0.84%)
Market Cap
$479.73M
Shares
13.39M
All earnings calls

Earnings call · FY2026 Q2

IBEX Ltd Q2 FY2026 Earnings Call

IBEX Ltd Q2 FY2026 Earnings Call

Concluded Feb 5, 2026 Audio replay
Feb 5, 2026 27:30 16 turns
Period
FY2026 Q2
Runtime
27:30
Sources
4 artifacts

Executive readout · one minute

What matters this quarter

IBEX delivered record Q2 FY2026 results with revenue up 17% to $164.2 million and adjusted EPS up 46% to $0.87, marking a fourth consecutive quarter of double-digit organic growth, and raised full-year revenue and Adjusted EBITDA guidance.

AI leadership and Wave iX platform 9 Margin trajectory and near-term headwinds 9 HealthTech vertical expansion 7 India expansion as a growth driver 7 New client wins and trophy accounts 7 Revenue growth and financial outperformance 5

Management tone

Confident

Net tone +82 · low hedging

Grounding quotes
  • “I'd like to start by recognizing the entire IBEX organization for delivering another outstanding quarter yet again.”
  • “I am pleased to report that the momentum we've built across the business accelerated in the second quarter, enabling us to deliver exceptional results with headline revenue growth of 17% and adjusted EPS growth of 46%.”
  • “this quarter marks our fourth consecutive period of double-digit organic revenue growth, well above competitive growth rates and underscores our clear differentiation.”
  • “We believe we are further along than any of our competitors in our AI solutions, partnerships and deployments.”

Forward guidance

2 guided metrics

Management's latest ranges and targets are included below.

Research coverage

4 live sources

Switch sources without leaving this page or losing your listening position.

Revenue $164.22M +16.7% YoY
Diluted EPS $0.83 +45.6% YoY
Net income $12.22M +31.8% YoY

Research materials

Open the source you need; every reader stays inside this workspace.

Key takeaways

What improved, and what deserves a closer read.

Constructive signals

  • Revenue grew 16.7% to $164.2M and adjusted EPS grew 46% to $0.87, both records.
  • Fourth consecutive quarter of double-digit organic revenue growth.
  • HealthTech revenue grew 35.1%, on track to reach $100M by fiscal year-end.
  • Adjusted EBITDA grew 25.2% to $20.7M; adjusted EBITDA margin expanded 80 bps to 12.6%.
  • Net income margin expanded 80 bps to 7.4%; top-10 clients grew 20%.
  • Raised full-year revenue guidance to $650M–$660M and Adjusted EBITDA guidance to $80M–$82M.

Risks & pressure points

  • Telecommunications vertical revenue declined 23.1%, described as expected.
  • Gross margin declined year-over-year, cited as headwinds from deferred training revenue and India ramp investment.
  • Capital expenditures now expected at the upper end of the previous $20M–$25M range.

Key moments

Jump directly to management's words in the synchronized transcript.

“Our market-leading growth, combined with our healthy balance sheet, are enabling strategic investments in our growing AI capabilities as well as further expansion into strategic markets and in top-performing geographies. We believe we are further along than any of our competitors in our AI solutions, partnerships and deployments.” Robert Dechant, CEO

Forward guidance

From the 8-K filed Feb 5, 2026.

Metric Guided
Revenue
Fiscal Year 2026
$620M – $630M
Adjusted EBITDA
Fiscal Year 2026
$80M – $82M

Quarter detail

How the reported period landed and where the business moved.

Revenue · regions

Offshore$85.81M +16.2% YoY
Onshore$39.45M +27.5% YoY
Nearshore$38.95M +8.5% YoY

Capital returned

Buybacks · derived
$2.79M
Full-screen source Call document